Osteoporosis Therapeutics in Asia-Pacific Markets to 2024-Growth Driven by ongoing Transition from Anti-resorptive Agents to Anabolic Therapies Rising Prevalence and Growing Awareness

Press Release

The New Report “Osteoporosis Therapeutics Market” published by Premium Market Insights, covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Osteoporosis is a “silent epidemic” and as per the WHO declarations, it is a priority health issue. Osteoporosis is a disruption of bone architecture and decrease in bone mass, leading to a number of complications including increased chances of bone fractures and reduced bone strength. The most common sites of osteoporosis are the spine, hip and forearm, although it also affects other body parts.

The chronic nature of the disease, which requires ongoing treatment, relatively high annual cost of therapy (ACoT) of premium therapies, increasing prevalence and awareness about the disease among the patients over a period of time, and growing demand for mainly anabolic therapies, with only one anabolic therapy currently available in the market, have made osteoporosis treatment a highly lucrative market.

The osteoporosis therapeutic market has become very competitive due to the high number of new drug approvals, although the majority of them are incremental innovations of existing therapies. Competition is fierce, particularly among bisphosphonates and selective estrogen receptor modulators (SERMs), which are mostly used as first-line therapy and dominate the treatment market for osteoporosis patients.

Get sample copy of “Osteoporosis Therapeutics Market” at: https://www.premiummarketinsights.com/sample/GBI00004588

Scope

-The current Asia-Pacific osteoporosis market contains novel products, including a humanized anti-sclerostin mAb, a synthetic peptide analog of human PTHrP, and a recombinant peptide and analogue of PTH.
-What are the competitive advantages of the novel drugs over current marketed drugs-
-Bisphosphonates and SERMs dominate the osteoporosis market. However, unmet needs exist in terms of safety and efficacy.
-Will the drugs under development fulfill the unmet needs of the osteoporosis market-
-The pipeline contains a range of molecule types and molecular targets, including those that are well established in osteoporosis, and novel, first-in-class therapies. There are over 136 active pipeline molecules, and most of the late-stage investigational drug candidates feature improved dosing regimens and administration routes in comparison to currently marketed products and combination therapies.
-Which classes of novel drugs are most prominent in the pipeline-
-What is the potential for pipeline products to address unmet needs in the osteoporosis market-
-Will the pipeline address unmet needs related to limited anabolic therapies for osteoporosis patients-
-Analysis of clinical trials since 2006 identified that the failure rates of osteoporosis molecules were highest in Phase III, with the overall attrition rate for osteoporosis standing at 83%.
-How do failure rates vary by stage of development, molecule type, and molecular target-
-How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development-
-Over the 2017-2024 forecast period, the Asia-Pacific osteoporosis therapeutics market is expected to increase in value at a compound annual growth rate of 5.9%.
-Which markets make the most significant contribution to the current market size-
-What are the epidemiology trends in these markets-
-Will new market entrants lead to substantial changes in annual therapy costs-
-How will immunotherapies such as Prolia contribute to growth-
-How will different treatment usage patterns impact growth in the five assessed Asia-Pacific markets-

Have any query? Enquire about report at: https://www.premiummarketinsights.com/discount/GBI00004588

Fundamentals of Table of Content:

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.5 Market by Application
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Osteoporosis Therapeutics Market Size
2.2 Osteoporosis Therapeutics Growth Trends by Regions
2.3 Industry Trends

3 Market Share by Key Players
3.1 Osteoporosis Therapeutics Market Size by Manufacturers
3.2 Osteoporosis Therapeutics Key Players Head office and Area Served
3.3 Key Players Osteoporosis Therapeutics Product/Solution/Service
3.4 Date of Enter into Osteoporosis Therapeutics Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
4.1 Global Osteoporosis Therapeutics Sales by Product
4.2 Global Osteoporosis Therapeutics Revenue by Product
4.3 Osteoporosis Therapeutics Price by Product

5 Breakdown Data by End User
5.1 Overview
5.2 Global Osteoporosis Therapeutics Breakdown Data by End User

Get Complete Report at: https://www.premiummarketinsights.com/buy/GBI00004588

Contact Us:                                          
Call: +91-20-67274191
Email: [email protected]

About Premiummarketinsights:

Premiummarketinsights.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.